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Clinical trials employing vaccination with prostate-spe-
cific membrane antigen (PSMA) loaded dendritic cells
(DC) in patients (pts) with advanced prostate cancer
yielded response rates of >30%. We decided for HLA-A2
restricted peptides derived from prostate stem cell antigen
(PSCA) and prostate specific antigen (PSA 1–3) because
both antigens are overexpressed in >85% of prostate can-
cer and were demonstrated to induce antigen specific T-
cell responses in vitro. Cell penetrating peptide (CPP) is a
peptide derived from the HIV-tat protein that prolongs
antigen presentation in vitro leading to enhanced antitu-
mor immunity in vivo. Therefore, half of the pts were
assigned to receive CPP-PSCA loaded DCs. The purpose of
this study is to assess feasibility, patient safety, PSCA-/
PSA-specific T-cell responses and tumor regression in vivo.
Pts were vaccinated s.c. in 14d intervals. Response was
assessed two weeks after the 4th vaccination. Delayed-
type hypersensitivity (DTH) was tested d4+d46. Immune
competence was monitored by HBV vaccination d1+d43.
So far, 9/12 planned pts completed vaccination. No toxic-
ities were observed. 5/9 pts achieved SD (3 with <50%
decrease, 2 with <50% increase in PSA), and 3 of these but
no non-responders developed a positive DTH after the 4th
vaccination. The addition of CPP did not correlate with
outcome. Responding pts received at mean two further
vaccinations 4 weeks apart. At a median follow-up of 8.6
months 70% of pts are alive compared to a reported OS of
59% and 28% at a follow-up of 6 and 11 months, respec-
tively for pts with metastatic, hormone-refractory disease
[1-3]. No peptide specific T-cells were detected in two pts
evaluated so far, however, the correlation of clinical and
DTH responses suggests a tumor specific immunity. Our
data indicate that vaccination with PSA/PSCA-peptide-
loaded, autologous DCs is safe and well tolerated. Vacci-
nation of more patients, long-term follow-up and com-
pletion of immune monitoring are needed to evaluate
anti tumor effects.
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